Biogen Inc. (Nasdaq: BIIB) presented Phase 2 data from its CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE